Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Strata Critical Medical (SRTA) Cash from Investing Activities (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Cash from Investing Activities for 7 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities rose 359.38% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $69.8 million through Dec 2025, up 6965.16% year-over-year, with the annual reading at $69.8 million for FY2025, 6965.16% up from the prior year.
  • Cash from Investing Activities for Q4 2025 was $18.3 million at Strata Critical Medical, up from $2.4 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $207.6 million in Q2 2022, with the low at -$320.8 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$16.6 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Cash from Investing Activities skyrocketed 20849.06% in 2022, then plummeted 548.01% in 2024.
  • Over 5 years, Cash from Investing Activities stood at $4.6 million in 2021, then tumbled by 90.02% to $462000.0 in 2022, then tumbled by 83.77% to $75000.0 in 2023, then surged by 5201.33% to $4.0 million in 2024, then skyrocketed by 359.38% to $18.3 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at $18.3 million, $2.4 million, and $28.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.